Hwang Sang-yeon, head of the private equity (PE) institutional sector at HB Investment and the designate for CEO of Hanmi Pharmaceutical, has joined the Hanmi Pharmaceutical board of directors.
At Hanmi Group's headquarters in Songpa-gu, Seoul, on the 31st, all agenda items passed at Hanmi Pharmaceutical's regular shareholders meeting, including the appointment of Hwang Sang-yeon, the new CEO of Hanmi Pharmaceutical, as an inside director.
CEO Park Jae-hyun stepped down from the board, and the incoming chief, Hwang Sang-yeon, newly joined the board.
The designate, Hwang, is a finance and investment expert who served as head of a securities firm's research center and as an investment chief at a global asset management firm, and it is the first time in 53 years since the founding that an outsider has taken the helm at Hanmi Pharmaceutical.
With this shareholders meeting as a turning point, Hanmi Pharmaceutical's board was newly reshuffled. In the director appointment agenda, Hwang Sang-yeon and Kim Na-young were appointed as inside directors, and Han Tae-jun and Kim Tae-yoon were appointed as outside directors.
Outside director Kim Tae-yoon was appointed as a Commissioner of the audit committee, and outside director Chae Yi-bae was newly appointed as an outside director who will serve as a Commissioner of the audit committee.
The National Pension Service also exercised its voting rights on the agenda of this shareholders meeting. The National Pension Service voted against the appointment of outside director Chae Yi-bae on the grounds that approval for post-retirement employment by the Public Official Ethics Committee had not been confirmed.
Agenda items such as partial amendments to the articles of incorporation, approval of the ceiling on directors' remuneration, and approval of the plan to hold and dispose of treasury shares were also passed as originally proposed.